Article Information
History
- October 20, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mohammad Shehab1,*,
- Mohamed Abu-Farha2,
- Fatema Alrashed3,
- Ahmad Alfadhli1,
- Khazna AlOtaibi4,
- Abdulla AlSahli5,
- Thangavel Alphonse Thanaraj6,
- Arshad Channanath6,
- Hamad Ali2,7,
- Jehad Abubaker2 and
- Fahd Al-Mulla6,*
- 1Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Kuwait
- 2Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, Kuwait
- 3Department of Pharmacy Practice, Faculty of Pharmacy, Health Sciences Center (HSC), Kuwait University, Jabriya, Kuwait
- 4Department of Internal Medicine, Adan hospital, Ministry of Health, Kuwait
- 5School of Medicine, University of Jordan, Aman, Jordan
- 6Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman, Kuwait
- 7Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Sciences Center (HSC), Kuwait University, Jabriya, Kuwait
- ↵*Corresponding authors:
Mohammad Shehab, Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah, Kuwait. Tel: (+965) 99633181. Email: dr_mshehab{at}hotmail.com. And Fahd Almulla, Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman, Kuwait; Tel: (+965) 22242999., Email: fahd.almulla{at}dasmaninstitute.org
Posted October 20, 2021.
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
